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Abstract: To improve the efficacy of drug delivery, active targeted nanotechnology-based drug 
delivery systems are gaining considerable attention as they have the potential to reduce side 
effects, minimize toxicity, and improve efficacy of anticancer treatment. In this work CUR-NPs 
(curcumin-loaded lipid-polymer-lecithin hybrid nanoparticles) were synthesized and functional-
ized with ribonucleic acid (RNA) Aptamers (Apts) against epithelial cell adhesion molecule 
(EpCAM) for targeted delivery to colorectal adenocarcinoma cells. These CUR-encapsulated 
bioconjugates (Apt-CUR-NPs) were characterized for particle size, zeta potential, drug encapsu-
lation, stability, and release. The in vitro specific cell binding, cellular uptake, and cytotoxicity of 
Apt-CUR-NPs were also studied. The Apt-CUR-NP bioconjugates exhibited increased binding 
to HT29 colon cancer cells and enhancement in cellular uptake when compared to CUR-NPs 
functionalized with a control Apt (P,0.01). Furthermore, a substantial improvement in cyto-
toxicity was achieved toward HT29 cells with Apt-CUR-NP bioconjugates. The encapsulation 
of CUR in  Apt-CUR-NPs resulted in the increased bioavailability of delivered CUR over a 
period of 24 hours compared to that of free CUR in vivo. These results show that the EpCAM 
Apt-functionalized CUR-NPs enhance the targeting and drug delivery of CUR to colorectal 
cancer cells. Further development of CUR-encapsulated, nanosized carriers will lead to improved 
targeted delivery of novel chemotherapeutic agents to colorectal cancer cells.
Keywords: PLGA-lecithin-PEG nanoparticles, curcumin, EpCAM, aptamer, targeted drug 
delivery
Introduction
One of the main goals of modern cancer chemotherapy is to deliver a safe and 
effective dose of therapeutic agents preferentially to disease site(s) while sparing 
normal tissues.1 To improve the efficacy of drug delivery, nanotechnology-based 
drug-delivery systems are gaining considerable attention, as they have the poten-
tial to reduce side effects, minimize toxicity, and improve anticancer treatment 
efficacy. Among these delivery systems, liposome and polymer nanoparticles (NPs) 
are the two most promising classes owing to their biocompatible and biodegrad-
able properties, and they have been approved for clinical use by the US Food and 
Drug Administration.2,3 However, these two first-generation nanomedicines utilize 
a “passive targeting” principle for cancer-drug delivery. The new generation of 
cancer nanodrug delivery systems seeks to adopt an “active targeting” approach, 
in addition to the passive targeting.
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Recently, biodegradable lipid-polymer hybrid nano-
particles that take advantage of the positive attributes of 
polymeric nanoparticles have emerged as a more attractive 
class of drug delivery carriers.3,4 The hybrid nanoparticles 
can be a robust drug-delivery platform using a single-step 
strategy of nanoprecipitation and self-assembly to achieve 
high drug-encapsulation efficiency, ease of manufacturing, 
tunable and sustained drug release, and good serum stability.4 
These hybrid nanoparticles are mainly composed of 1) poly 
(D, L-lactide-co-glycolide) (PLGA) as a hydrophobic core for 
encapsulating hydrophobic drugs; 2) lecithin as a monolayer 
around the PLGA core; and 3) 1,2-distearoyl-sn- glycero- 
3-phosphoethanolamine-N-carboxy(polyethylene gly col) 
2000 (DSPE-PEG
2000
-COOH) as a polyethylene glycol (PEG) 
shell that intersperses into the lipid shell to prolong the 
circulation half-life in vivo and to provide functionalization 
groups for the modification of targeting ligands.
A desirable attribute of a targeted cancer treatment is to 
deliver chemotherapeutic drugs to cancer cells over a suf-
ficient time without affecting the surrounding noncancerous 
tissues. This can be accomplished by targeting ligands that 
recognize tumor-specific or tumor-associated surface mark-
ers.5 Aptamers (Apts), single-stranded oligonucleotides 
selected via an in vitro process of systematic evolution of 
ligands by exponential enrichment, can be considered as the 
nucleic-acid analogs of antibodies.6 Apts have some favor-
able characteristics that could rival traditional antibodies, 
including small size, low immunogenicity, great stability 
over extreme conditions, and high affinity and specificity 
toward their targets.5,7
Curcumin (CUR) is a natural polyphenol present in tur-
meric (Curcuma longa) with low intrinsic toxicity but a wide 
range of biological activities, including antitumor, antioxi-
dant, and anti-inflammatory properties.8 From in vivo studies, 
it has been demonstrated that CUR is capable of inhibiting the 
growth of implanted human tumors and carcinogen-induced 
tumors.9 CUR mediates its antiproliferative, anti-invasive, 
and proapoptotic effects on cancer cells, including cancer 
stem/progenitor cells and their progenies, through multiple 
molecular mechanisms. However, CUR has low solubil-
ity (approximately 0.0004 mg/mL at pH 7.3) and limited 
bioavailability in the blood circulation when administered 
orally in humans, and it is degraded within 30 minutes at 
basic pH in aqueous solution, which greatly limits its utility 
in cancer treatment as a free drug.10,11 Various studies have 
shown that encapsulation of CUR in PLGA nanoparticles and 
liposomes can overcome such limitations.9,12,13 Most of these 
targeted CUR-PLGA nanoparticles tested are characterized 
by a size of about 200 nm.14 However, for cancer treatment, 
nanoparticles with a diameter of 30–200 nm are desirable, 
depending on the type of tumor in question, in order to 
 promote better tissue penetration and cellular uptake and 
longer blood circulation.15
To date, no study has encapsulated CUR with PLGA-
lecithin-PEG nanoparticles. Being a good dispersing agent, 
lecithin has promising traits as a nanomedicine carrier due to 
its ability to increase the stability and drug-loading beyond that 
which PLGA nanoparticles have achieved.16 In this study, we 
developed CUR-encapsulated small PLGA-lecithin-PEG nano-
particles (CUR-NPs) with a size of around 100 nm for address-
ing the solubility and low bioavailability of CUR and optimizing 
the particle size for better antitumor traits. Second, we function-
alized the CUR-NPs with an Apt against epithelial cell adhesion 
molecule (EpCAM), a protein that is overexpressed on colorec-
tal adenocarcinoma cells, to develop EpCAM Apt-CUR-NP 
bioconjugates. We then assessed whether these nanoparticle–
Apt bioconjugates could deliver drugs to colon cancer cells 
with specific targeting and enhancement of cellular uptake. We 
showed that these  Apt-CUR-NP conjugates exhibited a higher 
drug- encapsulating yield and a more-sustained drug-release 
profile than did free CUR. In addition, good cellular target-
ing toward colon cancer cells was observed for the conjugate, 
resulting in enhancement of cellular uptake and cytotoxicity. 
Our data suggest that the EpCAM Apt-functionalized CUR-NP 
is a promising drug-delivery carrier for colon cancer therapy.
Material and methods
Cells and reagents
All cell lines used were purchased from American Type 
Culture Collection (ATCC, Manassas, VA, USA), including 
HT29 (human colon cancer, EpCAM+) cells and HEK293T 
(human embryonic kidney, EpCAM−) cells. CUR was pur-
chased from Henan Zhongda Biological Engineering Co, 
Ltd (Zhengzhou City, People’s Republic of China). PLGA 
(lactide to glycolide ratio 50/50) with ester- terminated 
was obtained from Sigma-Aldrich (St Louis, MO, USA). 
 Pegylated phospholipid (DSPE-PEG
2000
-COOH) was 
obtained from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). 
Soybean lecithin consisting of 90%–95% phosphatidylcholine 
was obtained from MP Biomedicals (Solon, OH, USA). 
Amicon Ultra-4 centrifugal filters with a molecular weight 
cut-off of 10 kDa were obtained from EMD Millipore 
(Billerica, MA, USA). N-hydroxysuccinimide (NHS), 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), 
and penicillin/streptomycin solution were obtained from 
Sigma-Aldrich. All reagents were of analytical grade. 
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Trypan blue, trypsin (0.25%) and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay kit were 
purchased from Sigma-Aldrich. EpCAM Apt (sequence: 
5′-Cy5 – A(2′-F-C)G(2′-F-U)A(2′-F-U) (2′-F-C) (2′-F-C) 
(2′-F-C) (2′-F-U) (2′-F-U) (2′-F-U) (2′-F-U) (2′-F-C)G(2′-F-C)
G(2′-F-U)-C6-amino linker-3′; where F =2′-fluoro, molecular 
weight: 6345) and negative control Apt, (sequence: 5′-Cy5 – 
A(2′-O-Me-C)G(2′-O-Me-U)A(2′-O-Me-U) (2′-O-Me-C) 
(2′-O-Me-C) (2′-O-Me-C) (2′-O-Me-U) (2′-O-Me-U) 
(2′-O-Me-U) (2′-O-Me-U) (2′-O-Me-C)G(2′-O-Me-C)G(2′-
O-Me-U)- C6-amino linker-3′; where 2′-O-Me = 2′-methoxy, 
molecular weight: 6502) were synthesized by Biospring 
GmbH (Frankfurt, Germany). All other reagents were of 
analytical or chromatographic grade and purchased from 
Sigma-Aldrich.
Synthesizing of apt-CUr-NPs
Preparation of CUr-NPs
CUR-NPs were prepared from PLGA, soybean lecithin, 
and DSPE-PEG
2000
-COOH (or DSPE-PEG
2000
-Apt) using 
a nanoprecipitation technique with a slight modification.17 
PLGA (10 mg/mL) and CUR (1 mg/mL) were dissolved in 
acetonitrile and mixed together at a final concentration of 
5 mg/mL and 125 µg/mL, respectively. Lecithin and DSPE-
PEG
2000
-COOH (4:1, molar ratio) were dissolved in 4% 
ethanol aqueous at 20% of the PLGA polymer weight and 
heated at 65°C for 3 minutes. The PLGA/acetonitrile solution 
was then added to the lipid aqueous solution in a dropwise 
manner to allow self-assembly for 20 minutes. The organic 
solvent was eliminated at low pressure and at 37°C via rotary 
evaporation. The remaining organic solvent and free drug 
molecules were removed by washing the nanoparticle solu-
tion three times using a Microsep™ Advance Centrifugal 
Device (Pall Corporation, Ann Arbor, MI, USA; molecular 
weight cutoff of 10 kDa) and then suspended in distilled 
water. The nanoparticles were used immediately or stored 
at −4°C for later use.
Conjugation of apt-CUr-NPs
The conjugation of Apt to nanoparticles was achieved 
through an amide bond between the carboxylic groups of 
DSPE-PEG
2000
-COOH and an amino group at the 3′ end of 
the Apt with two steps. Initially, amine-terminated Apt was 
conjugated to the carboxyl-functionalized DSPE-PEG using 
EDC and NHS activation chemistry. Briefly, DSPE-PEG
2000
-
COOH was incubated with 100 µL of phosphate-buffered 
saline (PBS) (pH 6.0) containing 400 mmol/L EDC and 
100 mmol/L NHS for 30 minutes at room temperature with 
gentle shaking. The resulting NHS-activated DSPE-PEG
2000
-
COOH was covalently linked to prefolded amine-modified 
Apt with a molar ratio of Apt to DSPE-PEG
2000
-COOH of 
1:10 over 2 hours at room temperature. The reaction mixture 
was then washed with water three times using a Microsep™ 
Advance Centrifugal device (Pall Corporation, Ann Arbor, 
MI, USA; molecular weight cutoff of 3 kDa) for removing 
unbound Apts. The resulting DSPE-PEG
2000
-Apt conjugates 
were then used in the preparation of lipid–polymer combi-
national nanoparticles according to the synthesis protocol 
described above.
Determination of characteristics  
of the NPs
Particle size, zeta potential, and surface morphology
Dynamic light scattering analysis using a Zetasizer 
Nano-ZS instrument (Malvern Instruments Ltd, Malvern, 
Worcestershire, UK) was employed to analyze the size dis-
tribution of CUR-NPs and Apt-CUR-NPs in dispersion and 
the zeta potential of the particles. The shape and particle 
morphology of CUR-NPs and Apt-CUR-NPs were analyzed 
using a field emission transmission electron micrograph 
(JEM-2200-FS; JEOL, Peabody, MA, USA). One drop of 
the sample solution was deposited onto a carbon-coated 
copper grid that had been previously hydrophilized under 
ultraviolet (UV) light and air-dried at room temperature 
prior to examination under transmission electron micros-
copy (TEM).
Determination of the successful 
bioconjugates of apt to CUr-NPs
agarose gel electrophoresis
For confirmation of Apt conjugation, nanoparticles pre-
pared as described above were subjected to separation via 
electrophoresis using a 0.8% agarose gel. The electrophoresis 
was performed at 90 V for 90 minutes, followed by imaging 
and analysis using an Image Quant LAS 4000 (GE Healthcare 
Life Sciences, Pittsburgh, PA, USA).
Surface chemistry evaluation
The Apt conjugated to the surface of nanoparticles was 
confirmed on the basis of the surface chemistry measured 
by X-ray photoelectron spectroscopy (XPS). XPS spectra 
were obtained using an EscaLab 250XI spectrometer 
with a monochromated Al Kα source (1486.68 eV), 
hemispherical analyzer, and multichannel detector (Thermo 
Fisher Scientific, Waltham, MA, USA). The pass energy 
was fixed at 20 eV or 100 eV to ensure sufficient resolution 
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and sensitivity. Binding energies of elements were 
corrected with reference to silicon wafer SiSi2p (102 eV). 
The XPS spectrum was analyzed with the curve-fitting 
program XPSPEAK 4.1 (Informer Technologies, 
Inc., Pittsburgh, PA, USA), and involved background 
subtraction using Shirley routines and subsequent non-
linear least-squares fitting to mix Gaussian–Lorentzian 
functions.
Determination of drug encapsulation 
efficiency and loading capacity
The drug concentration was calculated using the linear 
portion of the calibration curve obtained by the UV spec-
trophotometer at 427 nm for serial drug concentrations. The 
entrapment efficiency (E [%]) of CUR loaded in PLGA-lipid 
nanoparticles was determined as follows: the nonencapsu-
lated CUR was separated from nanoparticles by filtration with 
a Microsep™ Advance Centrifugal Device (Pall Corporation; 
molecular weight cutoff of 10 kDa), followed by centrifuga-
tion at 21,000× g for 5 minutes. The cleared supernatant was 
used for the determination of the nonencapsulated CUR by 
UV spectrophotometry. The E (%) was calculated by the 
formula:
 
1− Nonincapsulated drug in thesupernatant
Total drug used for synthesizing
×100%
 
(1)
The yield corresponds to the ratio of CUR in nanopar-
ticles recovered to the total amount of dried nanoparticles. 
The Y (%) was calculated by:
 Y (%) = {[Drug]
in NPs
/[NPs]
total
} ×100%. (2)
Stability of encapsulated CUr in NPs
The stability of CUR in solution and nanoparticles in different 
PBS solutions (0.01 M phosphate, pH 7.4), with or without 
10% fetal bovine serum (FBS) was estimated by the UV 
spectrophotometry method. Free CUR and CUR-NPs were 
prepared to a final volume of 5 mL with a fixed concentra-
tion of 20 µg/mL and incubated in a shaker rotating at 100 
rpm at 37°C for 8 hours. Free CUR was dissolved in PBS 
with the help of dimethyl sulfoxide (DMSO; final concen-
tration 0.1% volume/volume [v/v]). At predetermined time 
points (0 hours, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 
5 hours, 6 hours, 7 hours, and 8 hours), 100 µL of solutions 
containing free CUR or  CUR-NPs were removed and mixed 
with 400 µL of acetonitrile to determine the concentration 
of CUR, as described above.
In vitro drug release
The release of CUR from CUR-NPs was analyzed in PBS 
(pH 7.4) containing 0.1% weight/volume (w/v) Tween-80 with 
continuous magnetic stirring at 100 rpm. Two mL of CUR-NPs 
was added into a Slide-A-Lyzer Dialysis Cassette (Thermo 
Fisher Scientific, Rockford, IL, USA; molecular weight cutoff 
of 2 kDa) and the cassette was placed into a beaker containing 
200 mL of the phosphate–Tween buffer as described above. The 
CUR-NPs were dialyzed with magnetic stirring for 72 hours at 
37°C. At specific times, a given volume of nanoparticles was 
withdrawn from the dialysis bag for analysis and the entire 
buffer solution in the beaker was removed and replaced with 
fresh buffer solution to maintain a sink condition. CUR was 
extracted from nanoparticles by acetonitrile, and concentrations 
in nanoparticles were determined as described above. A stan-
dard curve of CUR was prepared under identical conditions.
Targeted binding abilities  
of apt-CUr-NPs
HT29 cells or HEK293T cells were seeded in 35 mm 
glass-bottom dishes and incubated at 37°C in 5% CO
2
 for 
24 hours. The Dulbecco’s Modified Eagle’s Medium for 
HEK293T cells and McCoy’s 5A Medium for HT29 cells 
were then replaced with full culture medium (without phenol 
red) containing 4 µg/mL free CUR or equivalent amount of 
CUR-NPs, Apt-CUR-NPs, or control-Apt-CUR-NPs. One 
hour later, cells were washed twice with PBS and imaged for 
cellular uptake studies using a FluoviewFV10i fluorescence 
laser scanning confocal microscope (Olympus Corpora-
tion, Tokyo, Japan) at 37°C. The binding abilities obtained 
from confocal images were quantitatively analysed by the 
Image Pro program (Media Cybernetics, Inc., Rockville, 
MD, USA).
Cellular uptake study
CUR content in cells and plasma was determined using a 
high-performance liquid chromatography (HPLC) system 
consisting of an e2695 Separation Module and a 2475 Multi λ 
Fluorescence Detector (Waters Corporation, Milford, MA, 
USA) with the mobile phase composed of acetonitrile–2% 
glacial acetic acid (48:52, v/v) at a flow rate of 1.0 mL/minute 
at 25°C. The excitation and emission wavelengths were set at 
425 nm and 475 nm, respectively. Chromatographic separa-
tion was performed using a Nova-Pak® C
18
 column (Waters 
Corporation; 3.9×150 mm 4 µm) with a Nova-Pak® C
18
 guard 
column. All solvents for HPLC procedures were prepared 
freshly and filtered with 0.22 µm membrane before using.
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The stock solution of CUR (10 mM) was prepared in 
DMSO and diluted with the culture medium to obtain the 
desired concentrations. The final concentration of DMSO was 
less than 0.1% in the working culture medium. For loading 
of CUR, HT29 and HEK293T cells (1×106 cells/mL) were 
incubated with CUR at 20 nM for 30 minutes or 60 minutes, 
and washed thrice with cold PBS. For the estimation of cellular 
uptake, the pellet of washed and CUR-loaded cells was sus-
pended in 200 µL of acetonitrile and sonicated for 20 minutes, 
followed by centrifugation at 21,000×g for 10 minutes, and the 
concentration of CUR in the supernatant was determined by 
HPLC assay with the fluorescence detector. The estimated 
uptake at each point was expressed as pmoL/million cells and 
the vehicle control was performed for each cell line.
In vitro cell viability assay
The viability of cells was determined by the MTT assay, 
which measures the mitochondrial conversion of MTT to 
formazan as detected by the change of optical density at 
570 nm.12 After 24 hours of incubation, HT29 and HEK293T 
cells were exposed to free CUR, CUR-NPs, Apt-CUR-
NPs, or control-Apt-CUR-NPs for 2 hours at different 
concentrations (4 µg/mL and 8 µg/mL). The drug was then 
replaced with full culture medium (without phenol red) 
containing 1% penicillin/streptomycin and further incubated 
for 48 hours. Following the incubation, the medium was 
removed and 20 µL of MTT reagent was added into each 
well and incubated for another 4 hours. The reaction was 
terminated by removing MTT prior to the addition of 150 
µL/well DMSO. The absorbance of the wells, including 
the blanks, was measured at 570 nm using a VICTOR TM 
X5 Multilabel HTS Reader (PerkinElmer, Waltham, MA, 
USA). All experiments were performed in triplicate and 
repeated thrice.
Pharmacokinetics study in vivo
To investigate the pharmacokinetic properties of free CUR 
and CUR-NPs in vivo, male Sprague Dawley rats with body 
weights ranging from 250–300 g were randomly divided into 
two experimental groups (5–6 rats per group) with intrave-
nous administration of drugs at 4 mg/kg. The blood from the 
tail was serially collected into heparinized tubes at 0 minutes, 
5 minutes, 15 minutes, 30 minutes and 1 hour, 1.5 hours, 
2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, and 
24 hours. To separate the plasma and blood cells, blood 
samples (200 µL) were centrifuged at 10,000× g at 4°C for 
10 minutes and the supernatant was stored at −20°C until the 
determination of CUR by HPLC.
Statistical analysis
All data are shown as the mean ± standard deviation. One-way 
analysis of variance was used to identify statistical significance 
among groups. Statistical significance was set at P,0.05.
Results
generation and characterization 
of the nanoparticles
To generate the nanoparticle-Apt bioconjugates for targeted 
drug delivery to cancer cells, we used the nanoprecipitation 
method to encapsulate CUR within PLGA-PEG-COOH 
nanoparticles followed by the conjugation of the EpCAM 
Apt (Figure 1A). Structurally, this vehicle is composed of 
a hydrophobic polymeric core made of PLGA and CUR, 
a lipid layer composed of lecithin and DSPE-PEG
2000
-COOH 
with the link of Apt. The polymeric core and the lipid shell 
are associated through hydrophobic interactions, van der 
Waals forces, electrostatic interactions, or other noncova-
lent forces; the hydrophilic polymer stealth layer is often 
conjugated to the lipid shell through covalent bonds.17 The 
surface morphology of CUR-NPs and Apt-CUR-NPs was 
determined by TEM, and these nanoparticles showed narrow 
size distribution (polydispersity index: P,0.2) (Figure 1B). 
The physicochemical characteristics of formed nanoparticles 
were determined by their size, surface charge (zeta potential), 
CUR encapsulation, and surface morphology, which are sum-
marized in Table 1. Bioconjugation of Apts to CUR-NPs led 
to a slight increase in particle size (from 86.11±1.4 nm to 
90±1.9 nm), and more negative zeta potential (−26.9±2.7 mV 
to −36.3±4.2 mV and −39.9±3.7 mV, EpCAM Apt and 
negative control Apt bioconjugates respectively). The CUR 
encapsulated efficiency of CUR-NPs and Apt-CUR-NPs 
were 90.13%±4.2% and 89.98%±3.8%, respectively (n=3). 
Unlike free CUR, which has poor solubility in aqueous 
media, the aqueous solubility of CUR-NPs was improved 
greatly; the increased surface area due to the reduction of 
particle size, together with advanced biocompatibility of 
PLGA and PEG may contribute to the remarkable enhance-
ment of solubility.
Confirmation of the NP–Apt 
bioconjugates
The conjugation of the EpCAM Apt to CUR-NPs was deter-
mined by agarose gel electrophoresis. As shown in Figure 2A, 
the migration of the free EpCAM Apts matched that of the 
19 base pairs (bp) size marker, while both of the positive and 
control Apt-CUR-NP bioconjugates almost stayed at the origin. 
To confirm the solid conjugation of Apt-CUR-NPs, free Apt 
International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1088
li et al
and CUR-NPs were mixed together without any conjugation 
process and subjected to gel electrophoresis; these two ele-
ments were well separated on the gel. Taken together, the 
data reveal the efficient conjugation between the CUR-NPs 
and EpCAM Apt.
The successful attachment of Apt (−NH
2
) to PLGA-
CUR-PEG nanoparticles (−COOH) was further confirmed 
by N1 peak in XPS for identification of chemical species on 
particle surfaces (Figure 2B). The spectrum of nitrogen (N) 
indicates the formation of an amide bond by the EDC/NHS acti-
vation and attachment of Apt to nanoparticles, confirming the 
surface structure of Apt-modified CUR-NPs. A prominent peak 
(399.7 eV) of nitrogen originating from the C=N double bond 
nitrogen of the imidazole ring in ribonucleic acid (RNA) was 
obtained, demonstrating the attachment of NH
2
-Apt to CUR-
NPs. The peak at 133.6 eV was attributed to P2p envelope, 
which could only be ascribed to Apt according to the chemical 
composition of the sample. These data clearly confirm that the 
Apts have been successfully conjugated to CUR-NPs.
Drug stability in nanoparticles  
and in vitro release study
The stability of anticancer drugs for avoiding biodegradation 
in vivo is a major challenge for targeted delivery of  therapeutic 
agents, especially for CUR. To study the stability of CUR in 
our nanoparticles, free CUR and CUR-NPs were incubated at 
physiological pH 7.4 with or without 10% FBS followed by 
determination of CUR retention with a UV spectrophotometer. 
As shown in Figure 3A, more than 95% of free CUR under-
went rapid degradation in PBS after 6 hours of incubation. 
In contrast, the majority of CUR in CUR-NPs remained in 
PBS with and without 10% FBS, and approximately 75% of 
CUR remained stable. Therefore, encapsulation of CUR into 
PLGA-lecithin-PEG nanoparticles significantly improved 
its stability by protecting the encapsulated CUR against 
biodegradation.
Following determination of the CUR retention, we 
proceeded to investigate the in vitro release of CUR from 
CUR-NPs and Apt-CUR-NPs in PBS (pH 7.4, containing 
0.1% Tween-80). We added 0.1% Tween-80 to the dialysis 
buffer to generate a sink condition for CUR, as it is poorly 
soluble in PBS. A similar rapid release of about 50% 
CUR from all nanoparticles was observed after 8 hours of 
incubation, followed by a steady continued release pattern 
afterward (Figure 3B). The initial burst release might be 
due to the dissociation of surface-absorbed drugs present in 
the amphipathic lipid fence, while the sustained release was 
likely due to the slow release of CUR entrapped inside the 
polymer matrix. Thus, the results indicate that the encapsula-
tion of CUR in PLGA-lecithin-PEG nanoparticles affords its 
continuous and prolonged release.
A
B CUR-NPs
100 nm
Apt-CUR-NPs
Apt-CUR-NPs
Ctrl-Apt-CUR-NPs
Normal
endothelium
Normal cells
Cancer cells
Cancer cells
Cancer
endothelium
Apt-CUR-NPs
EpCAM aptamer
EpCAM protein
DSPE-PEG-COOH
Self-assembly
CURPLGA
Lipid
100 nm 100 nm
Figure 1 Synthesization and characterization of apt-CUr-Plga-lecithin-PEg NPs.
Notes: (A) Preparation of apt-CUr-Plga-lecithin-PEg NPs by nanoprecipitation and self-assembly technique. (B) TEM images of formed nanoparticles. The 
scale bar =100 nm; TEM magnification =400,000×.
Abbreviations: apt, aptamer; CUr, curcumin; DSPE-PEg-COOH, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-carboxy(polyethylene glycol) 2,000; EpCaM, epithelial 
cell adhesion molecule; NPs, nanoparticles; PEg, polyethylene glycol; Plga, poly (D, l-lactide-co-glycolide); TEM, transmission electron microscopy.
Table 1 Particle size, zeta potential, drug encapsulation efficacy, 
and polydispersity index for CUr-NPs, control-apt-CUr-NPs, 
and apt-CUr-NPs
Formulation Particle  
size ± SD  
(nm)
Zeta  
potential ± 
SD (mV)
Drug 
encapsulation ± 
SD (%)
PDI
CUr-NPs 86.1±1.4 −26.9±2.7 90.13% ±4.2% ,0.2
Control-apt-
CUr-NPs
88.5±2.3 −39.9±3.7 86.53% ±2.7% ,0.2
apt-CUr-NPs 90.2±1.9 −36.3±4.2 89.98% ±3.8% ,0.2
Abbreviations: apt, aptamer; CUr, curcumin; PDI, polydispersity index; NPs, 
nanoparticles; SD, standard deviation.
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Figure 2 Determination of successful bioconjugates of apt to CUr-Plga-lecithin-PEg NPs.
Notes: (A) Confirmation of Apt-CUR-NP bioconjugate formation by gel electrophoresis. The migration of free EpCAM apts matched that of the 19 bp size marker, while 
both of the positive and control apt-CUr-NP bioconjugates almost stayed at the origin. The free apt and CUr-NPs mixed together without any conjugation process were 
well separated on the gel. ladder 1, 20 bp size ladder; ladder 2, 200 bp size ladder. (B) XPS spectra of apt-CUr-NPs. The prominent peak (399.7 eV) of nitrogen (N) 
originating from the C=N double bond nitrogen of the imidazole ring in rNa was obtained demonstrating the attachment of NH2-apt to CUr-NPs. The peak at 133.6 eV 
was attributed to P2p envelope, which could only be ascribed to apt according to the chemical composition of the sample.
Abbreviations: apt, aptamer; Ctrl, control; CUr, curcumin; NP, nanoparticle; PEg, polyethylene glycol; Plga, poly (D, l-lactide-co-glycolide); rNa, ribonucleic acid; XPS, 
X-ray photoelectron spectroscopy; bp, base paires.
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The binding of Apt-CUR-NP bioconjugates to HT29 
cells and the subsequent internalization was studied using 
 confocal microscopy. As shown in Figure 4A, the conju-
gation of Apt to CUR-NPs led to significantly enhanced 
internalization of the EpCAM Apt CUR-NP conjugates to 
HT29 cells compared with the conjugates using the negative 
control Apt, which has the same nucleic acid sequence but 
different chemical modification and thus abolished its abil-
ity to bind to EpCAM. There was no gross difference in the 
binding of EpCAM- negative HEK293T cells between the 
International Journal of Nanomedicine 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1090
li et al
bioconjugates and the control group. The cell binding and 
internalization of Apt-CUR-NPs and control were further quan-
tified using the Image Pro program. As shown in Figure 4B, 
the data demonstrates a 64-fold enhancement in the binding 
and/or  internalization of Apt-CUR-NP bioconjugates to 
HT29 cells compared with CUR-NPs functionalized with 
the negative control Apt.  However, there was a remark-
ably low binding efficiency of nanoparticles in nontargeted 
HEK293T cells, which was most likely due to nonspecific 
phagocytosis, a phenomenon known to exist in many cells 
toward nanoparticles. The binding of bioconjugates to HT29 
cells was observed at an early incubation stage (5 minutes), 
while the differential binding and internalization of 
Apt-CUR-NP bioconjugates became markedly pronounced 
after 60 minutes (data not shown). These results demonstrate 
that Apt-CUR-NP bioconjugates can enhance the delivery of 
CUR to EpCAM-expressing HT29 colorectal cancer cells.
Confocal microscopy revealed a particulate pattern for 
both CUR fluorescence and Apt fluorescence in HT29 cells 
treated with Apt-CUR-NP bioconjugates (Figure 4). In con-
trast, in HT29 cells treated with CUR-NPs  conjugated with 
the negative control Apt and HEK293T cells, the fluorescence 
for CUR lacked such a particulate pattern. This particulate 
pattern is indicative of endocytosis, as we previously showed 
for the EpCAM Apt upon binding to HT29 cells.18 Following 
the demonstration of Apt-CUR-NPs binding to HT29 cells 
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Figure 3 Stability and release profile of free CUR and CUR-NPs.
Notes: (A) Stability of encapsulated CUr in nanoparticles. More than 95% of free CUr underwent rapid degradation in PBS at pH 7.4 after 6 hours of incubation, while 
approximately 75% of CUr in CUr-NPs remained stable with and without 10% FBS. (B) Drug-release profile from CUR-NPs and Apt-CUR-NP conjugates. A similar rapid 
release of about 50% CUr from all nanoparticles was observed after 8 hours of incubation, followed by a steady continued release pattern afterward.
Abbreviations: apt, aptamer; Ctrl, control; CUr, curcumin; FBS, fetal bovine serum; h, hour; NP, nanoparticle; PBS, phosphate-buffered saline.
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qualitatively using microscopy, we next sought to confirm 
the differential uptake of the Apt-CUR-NP bioconjugate 
quantitatively using HPLC. In a 30-minute time course study, 
the relative cellular uptake of Apt-CUR-NPs was found to 
be 138.0 pmol per 1×106 cells, compared with 86.6 pmol, 
107.2 pmol, and 113.6 pmol per 1×106 cells for free CUR, 
control-CUR-NPs, and CUR-NPs, respectively (Figure 5). 
There were statistically significant differences between Apt-
CUR-NPs and free CUR groups (P,0.01, n=5), while the 
differences between Apt-CUR-NPs and the other two groups 
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Figure 4 Selective internalization of apt-functionalized CUr-Plga-lecithin-PEg nanoparticles to colon cancer cells.
Notes: (A) Targeted binding of Apt-CUR-NPs was confirmed by confocal microscopy. The conjugation of apt to CUR-NPs led to significantly enhanced internalization of the 
EpCaM apt-CUr-NP conjugates to HT29 cells compared with the conjugates using the negative control apt; there was no gross difference in the binding of EpCaM-negative 
HEK293T cells between the bioconjugates and the control group. (B) Mean fluorescence intensity of the cell binding and internalization of Apt-CUR-NPs.
Abbreviations: apt, aptamer; Ctrl, Control; CUr, curcumin; EpCaM, epithelial cell adhesion molecule; HEK293T, human embryonic kidney cells; HT29, human colon 
cancer cells; NP, nanoparticle.
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(control-CUR-NP, and CUR-NP) were also statistically 
significant (P,0.05, n=5). Similar results were observed 
after 60-minutes incubation of cells with different groups in 
which cellular uptakes in the free CUR, control- CUR-NPs, 
and CUR-NPs were all statistically significantly different 
compared with Apt-CUR-NPs. This differential uptake of 
bioconjugates by HT29 cells was reproducibly observed with 
cells of different passage numbers. Thus, these results sug-
gest that Apt-CUR-NPs are capable of efficiently  targeting 
HT29 cells and delivering CUR inside HT29 cells via 
endocytosis.
In vitro cell viability assay
After the confirmation of the ability of the Apt-NP bioconju-
gates to deliver CUR to target cells, we further evaluated the in 
vitro antiproliferation activity of free CUR, NPs alone, CUR-
NPs, Apt-CUR-NPs, and control-Apt-CUR-NPs against both 
HT29 and HEK293T cells using a cell viability assay (MTT). 
Cells were treated with the respective reagent for 2 hours fol-
lowed by 48-hour incubation in drug-free media, and the cell 
viability was determined. As shown in Figure 6, Apt-CUR-
NPs were more cytotoxic to colorectal cancer HT29 cells than 
all controls at the concentration equivalent of 4 µg/mL CUR. 
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Figure 5 apt-CUr-NPs selectively and effectively deliver drugs to targeted cells.
Notes: In a 30-minute time course study, the relative cellular uptake of apt-CUr-NPs was found to be 138.0 pmol per 1×106 cells, compared with 86.6 pmol, 107.2 pmol, 
and 113.6 pmol per 1×106 cells for free CUr, control-apt-CUr-NPs, and CUr-NPs, respectively. Values shown are means ± standard deviation for three independent 
experiments (n=5 in each group). The data are significantly different at *P,0.05; **P,0.01.
Abbreviations: apt, aptamer; Ctrl, control; CUr, curcumin; EpCaM, epithelial cell adhesion molecule; n, number; NPs, nanoparticles.
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in these groups (data not shown). Taken together, these results 
indicate that CUR-NPs bioconjugated with EpCAM Apt could 
effectively deliver drugs to EpCAM-expression colorectal 
cancer cells in vitro.
Pharmacokinetics study in vivo
The systemic pharmacokinetics and bioavailability after 
intravenous administrations of 4 mg/kg of free CUR and an 
equivalent dose of CUR-NPs are summarized in Table 2. After 
the intravenous administration of free CUR suspension, a maxi-
mum plasma concentration of approximately 1,502.66±559.55 
ng/mL was observed in 5 minutes.  Thereafter, the free CUR 
was diminished abruptly and became undetectable in the serum 
6 hours after administration, as the drug was distributed and 
rapidly metabolized, resulting in a short elimination half-time 
of approximately 1.07 hours. In a sharp contrast, a sustained 
release of CUR over 24 hours was observed when it was 
delivered by CUR-NPs; the maximum plasma concentration 
reached 1487.51±503.49 ng/mL even after 2-hour administra-
tion, contributing to a significant increase of t
1/2
 (about sixfold) 
compared with that of free CUR (P,0.01). There was a statisti-
cally significant difference in both area under the curve (AUC)
(0–t)
 and AUC
(0–∞) between free CUR and CUR-NPs (P,0.05). 
In addition, the CUR from CUR-NPs presented a relative 
bioavailability threefold superior to that of free CUR.
Table 2 Summary of pharmacokinetic parameters for free CUr 
and CUr-NPs
Pharmacokinetic  
parameters
Free CUR solution CUR-NPs
t1/2 β (h) 1.07±0.45 5.93±1.55**
aUC(0–t) (µg/l*h) 1,529.25±259.69 3,321.43±1,779.78#
aUC(0–∞) (µg/l*h) 1,697.49±259.61 3,415.83±1,829.94#
Cmax (ng/l) 1,502.66±559.55 1,487.51±503.49
Cl (l/h/kg) 2.40±0.33 1.22±1.46
MrT(0–t) (h) 1.18±0.39 3.02±0.42
Notes: Values shown are means ± standard deviation for three independent exper-
iments (n=5 in each group). The data are significantly different at **P,0.01; #P,0.05.
Abbreviations: aUC, area under the plasma concentration-time curves; Cl, total 
body clearance; Cmax, maximum plasma concentration; CUr, curcumin; MrT, mean 
retention time; n, number; NPs, nanoparticles; t1/2, elimination half-life; h, hour.
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Figure 6 Measurement of the cytotoxicity effects of apt-CUr-NPs to cancer cells by MTT assay.
Notes: Free CUR was toxic against both HT29 and HEK293T cells, the Apt-CUR-NP bioconjugate was significantly more potent against the EpCAM-expressing HT29 cells 
relative to the EpCaM-negative HEK293T cells (cell viabilities 58.9%±2.6% and 72.4%±1.3%, respectively, P,0.05). Values shown are means ± standard deviation for three 
independent experiments (n=5 in each group). *The data are significantly different at P,0.01.
Abbreviations: apt, aptamer; CUr, curcumin; EpCaM, epithelial cell adhesion molecule; HEK293T, human embryonic kidney cells; HT29, human colon cancer cells; 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NPs, nanoparticles.
While free CUR was toxic against both HT29 and HEK293T 
cells, the Apt-CUR-NP bioconjugate was  significantly more 
potent against the EpCAM-expressing HT29 cells relative 
to the EpCAM-negative HEK293T cells (cell viabilities 
58.9%±2.6% and 72.4%±1.3%,  respectively, P,0.05). The 
data indicated that the cytotoxicity of Apt-CUR-NPs was more 
enhanced than that of free CUR. The observed cytotoxicity of 
Apt-CUR-NPs to HEK293T cells was likely due to uptake of 
CUR released after the dissociation of CUR from CUR-NP 
bioconjugates. In addition, similar inhibitory effects were 
obtained when the CUR concentration increased to 8 µg/mL 
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Discussion
Chemotherapy agents used for cancer therapy have limited 
efficacy mainly due to their low specificity toward cancer cells 
and poor pharmacobioavailability in vivo, resulting in inci-
dence of normal tissue toxicity and major side effects.19–21 To 
address the problem, there is a high demand to explore thera-
peutic modalities with no or minimal side effects to normal 
cells. In this case, the study of using targeting molecules for 
cancer-specific therapy, linking to nanosized drug carriers, 
has been a promising strategy for targeted drug delivery and 
controlled drug release in the battle against cancer.5,22 In this 
study, we synthesized a bioconjugate composed of an RNA 
Apt specifically targeting the EpCAM protein of colorectal 
adenocarcinoma cells and CUR-encapsulated PLGA-lecithin-
PEG-nanoparticles, and we performed a series of in vitro 
studies to demonstrate that the Apt-CUR-NP bioconjugate 
can efficiently deliver CUR to colon cancer cells.
A variety of elements should be taken into consideration 
in order to synthesize a drug-encapsulated nanoparticle with 
high efficiency, including selecting the right polymer compo-
sition, a reliable solvent for good drug solubility, and a solid 
technique.19,23 We chose the nanoprecipitation method to syn-
thesize nanoparticles with lecithin-surrounded PLGA and its 
derivatives for the purpose of highly efficient encapsulation 
of CUR (90.13% ±4.2%); the reaction condition for nanopre-
cipitation was gentle, which could minimize the probability 
of structural damage of Apt.19,24 Since we plan to explore a 
functional drug nanocarrier using Apts for targeted delivery 
of drug-released nanoparticles to specific cells, along with 
the fact that EpCAM represents a well-characterized target 
of cancer stem cells in colon cancer, we selected the RNA 
Apt against EpCAM proteins of colorectal adenocarcinoma 
cells to generate the nanoparticle–Apt bioconjugates.
The mean size of generated bioconjugate nanoparticles 
including both CUR-NPs and Apt-CUR-NPs was smaller 
than 100 nm (about 90 nm), which is consistent with the 
notion that particle size less than 150 nm is desirable for 
promising extravasation of tumor microvasculature and 
tumor accumulation.25 Zeta potential is another important 
index for the stability of nanoparticle formulations, because 
high values can prevent the aggregation of nanoparticles in 
buffer due to strong repellent forces.26 Particles that are gen-
erated from PLGA are expected to have a slightly negative 
surface charge, a desirable characteristic as particles with 
a negative surface charge may specifically interact with 
the negatively charged Apts and increase their binding 
characteristics.27,28 In this study, the zeta potentials of CUR-
NPs and Apt-CUR-NPs were −26.9 mV and −36.3 mV, 
respectively. It is possible that the conjugation of carboxylic 
acid functional groups in the terminal ends of polymers with 
amino groups in Apts resulted in additional negative charge 
on the surface of the nanoparticles, which could minimize 
the interaction between Apts and nanoparticles.17,29
Surface composition of nanoparticles is a key determi-
nant of the drug bioavailability and other pharmacokinetic 
parameters.30,31 In this study, CUR was encapsulated into 
PLGA-lecithin-PEG. The formed CUR-NPs had a signifi-
cantly increased half-life and mean retention time compared 
with that of free CUR (approximately sixfold and threefold, 
respectively). The approach of PEGylation has been used to 
prolong the circulation half-life, and it is useful for  minimizing 
nanoparticle aggregation and beneficial in preventing the 
clogging of small vasculature and improving size-based tar-
geting, which may also minimize the interaction between the 
conjugated Apts with the nanoparticle surface.32–34 The drug 
release from PLGA nanoparticles is a complicated process and 
many factors can affect the process, including the nanoparticle 
diffusion, degradation speed, stability of the protected layer, 
and physicochemical properties of drugs.19,23 Our CUR-NPs 
exhibited an initial release of CUR, which is understandable 
because of the burst release of deposited or weakly attached 
drugs on the nanoparticle surface.19,35 The sustained release 
of CUR from CUR-NPs was consistent with previous stud-
ies for the release process of encapsulated anticancer drugs 
from PLGA-NPs.35,36 Also, consistent with the literature,17,29 
we demonstrated that the attachment of Apt to nanoparticles 
does not affect the drug release from the lipid–polymer, as the 
payload release profile was not significantly different between 
CUR-NPs and Apt-CUR-NPs.
To study whether the Apt-functionalized bioconjugate 
could selectively and effectively deliver drugs to colon cancer 
cells, the HT29 cell line with abundant EpCAM proteins on 
cell surfaces was chosen as a model, with HEK293T cells that 
do not express EpCAM as a negative control.18 Indeed, the 
binding of Apt-CUR-NPs to HT29 cells was increased when 
compared with that of control-Apt-CUR-NPs as well as with 
the EpCAM-negative cell line HEK293T. To complement 
the results achieved from confocal microscopy, we further 
quantitatively evaluated the cellular uptake of CUR-NPs and 
Apt-CUR-NPs in HT29 cells using an HPLC assay to verify 
the enhancement uptake of Apt-CUR-NPs by colon cancer 
cells. The data demonstrate that the average cellular uptake 
of CUR in Apt-CUR-NPs by HT29 cells was statistically 
significantly higher than that in all control groups. It is con-
sidered that the targeted therapeutic effect of nanoparticles is 
a strategy of increased internalization and enhanced retention 
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of the drug-loaded nanoparticles within targeted cells.37 In 
this study, the targeted drug delivery of Apt-CUR-NP bio-
conjugate offers increased drug sensitivity and enhancement 
of drug cellular uptake. In order to further study whether the 
Apt–nanoparticle bioconjugate can be useful for targeted drug 
delivery, we compared in vitro cytotoxicity induced by Apt-
CUR-NPs, free CUR, and other controls in the HT29 cell line. 
Cells treated with Apt-CUR-NPs produced more cytotoxicity 
than the control-Apt-CUR-NPs and free CUR; these results 
were consistent with cellular uptake results. The enhanced 
toxicity of Apt-CUR-NPs in colon cancer cells was likely 
due to EpCAM Apts attached to the surface of nanoparticles 
that facilitate the targeting of Apt-CUR-NPs to HT29 cells, 
followed by the endocytosis of nanoparticles and drug release 
inside of targeted cells. Of note, in in vitro cellular assays, cells 
are displayed as a monolayer and exposed to a constant drug 
concentration; this pattern cannot offer a reliable prediction 
of therapeutic effects in vivo because of that cells are exposed 
to different drug levels after the drug absorption. Therefore, it 
is important to evaluate the pharmacokinetic characteristic in 
vivo after the intravenous administration of CUR-NPs and free 
CUR. The results demonstrate that the half-life of CUR-NPs 
was 5 hours longer than that of free CUR. It is likely that solid, 
larger-size lipid–polymer nanoparticles could prolong drug 
circulation in vivo and thus facilitate the effective delivery of 
the payload to tumors due to extended systemic exposure.
In conclusion, we developed a targeted drug delivery 
carrier composed of curcumin-encapsulated nanoparticles 
and EpCAM RNA Apts. These multifunctional Apt-CUR-NP 
bioconjugates can be used as effective therapeutic modalities 
to deliver drugs to colon cancer cells, resulting in the selective 
and effective delivery of CUR to EpCAM-expressing cancer 
cells with enhancement of cellular uptake. This bioconjugate 
system could be further developed as a potential approach for 
both the detection and killing of colorectal adenocarcinoma 
cells. Further validation of Apt-CUR-NP bioconjugates in 
additional in vivo studies will lead to improvement of CUR 
delivery after systemic administration for targeted cancer 
treatment.
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